PET scan imaging in oncology.

Fluorodeoxyglucose F18/diagnostic use; Follow-Up Studies; Humans; Neoplasm Staging/methods; Neoplasms/radionuclide imaging; Radiopharmaceuticals/diagnostic use; Tomography, Emission-Computed/methods

Abstract :

[en] With the emergence of positron emission tomography (PET) from research laboratories into routine clinical use, it is important to redefine the most appropriate use of each imaging technique. The aim of this review article is to show the potential of PET in oncology. We discuss the most promising indications and the perspectives for the future. We will also point out the shortcomings and the important questions to be answered before fully considering PET as a necessary tool in the day-to-day practice of oncology. Although many studies have documented the high accuracy of 18F-FDG PET for the detection and staging of malignant tumours and for the monitoring of therapy results in these patients, it is very important to assess the impact of the technique on patient outcome and to show cost-effectiveness from the societal viewpoint.

Disciplines :

Hematology

Author, co-author :

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

PET scan imaging in oncology.

Publication date :

2003

Journal title :

European Journal of Cancer

ISSN :

0959-8049

eISSN :

1879-0852

Publisher :

Elsevier Science, Oxford, United Kingdom

Volume :

Issue :

Pages :

1525-34

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 March 2009

Statistics

Number of views

90 (1 by ULiège)

Number of downloads

60 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Jerusalem, G., Hustinx, R., Beguin, Y., Fillet, G., The value of positron emission tomography (PET) imaging in disease staging and therapy assessment (2002) Ann. Oncol., 13 (SUPPL. 4), pp. 227-234
Gluecker, T.M., Fletcher, J.G., CT colonography (virtual colonoscopy) for the detection of colorectal polyps and neoplasms. current status and future developments (2002) Eur. J. Cancer, 38, pp. 2070-2078
Miles, K.A., Functional computed tomography in oncology (2002) Eur. J. Cancer, 38, pp. 2079-2084
Griffiths, J.R., Tate, A.R., Howe, F.A., Stubbs, M., Magnetic resonance spectroscopy of cancer - Practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma (2002) Eur. J. Cancer, 38, pp. 2085-2093
Blomley, M.J., Eckersley, R.J., Functional ultrasound methods in oncological imaging (2002) Eur. J. Cancer, 38, pp. 2108-2115
Padhani, A.R., Functional MRI for anticancer therapy assessment (2002) Eur. J. Cancer, 38, pp. 2116-2127
Evans, J.W., Peters, A.M., Gamma camera imaging in malignancy (2002) Eur. J. Cancer, 38, pp. 2157-2172
Gupta, N., Price, P.M., Aboagye, E.O., PET for in vivo pharmacokinetic and pharmacodynamic measurements (2002) Eur. J. Cancer, 38, pp. 2094-2107
Blasberg, R., PET imaging of gene expression (2002) Eur. J. Cancer, 38, pp. 2137-2146
Gallagher, B.M., Fowler, J.S., Gutterson, N.I., Metabolic trapping as a principle of radiopharmaceutical design: Some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose (1978) J. Nucl. Med., 19, pp. 1154-1161
Yasuda, S., Ide, M., Fujii, H., Application of positron emission tomography imaging to cancer screening (2000) Br. J. Cancer, 83, pp. 1607-1611
Gould, M.K., Maclean, C.C., Kuschner, W.G., Rydzak, C.E., Owens, D.K., Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis (2001) JAMA, 285, pp. 914-924
Gambhir, S.S., Shepherd, J.E., Shah, B.D., Analytical decision model for the cost-effective management of solitary pulmonary nodules (1998) J. Clin. Oncol., 16, pp. 2113-2125
Sperti, C., Pasquali, C., Chierichetti, F., Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas (2001) Ann. Surg., 234, pp. 675-680
Sendler, A., Avril, N., Helmberger, H., Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: Diagnostic limitations (2000) World J. Surg., 24, pp. 1121-1129
Kasperk, R.K., Riesener, K.P., Wilms, K., Schumpelick, V., Limited value of positron emission tomography in treatment of pancreatic cancer: Surgeon's view (2001) World J. Surg., 25, pp. 1134-1139
Kole, A.C., Nieweg, O.E., Pruim, J., Detection of unknown occult primary tumors using positron emission tomography (1998) Cancer, 82, pp. 1160-1166
Aassar, O.S., Fischbein, N.J., Caputo, G.R., Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors (1999) Radiology, 210, pp. 177-181
Greven, K.M., Keyes J.W., Jr., Williams D.W. III, McGuirt, W.F., Joyce W.T. III, Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose (1999) Cancer, 86, pp. 114-118
Lassen, U., Daugaard, G., Eigtved, A., Damgaard, K., Friberg, L., 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT) (1999) Eur. J. Cancer, 35, pp. 1076-1082
Bohuslavizki, K.H., Klutmann, S., Kroger, S., FDG PET detection of unknown primary tumors (2000) J. Nucl. Med., 41, pp. 816-822
Rades, D., Kuhnel, G., Wildfang, I., Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management (2001) Ann. Oncol., 12, pp. 1605-1609
Dwamena, B.A., Sonnad, S.S., Angobaldo, J.O., Wahl, R.L., Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT (1999) Radiology, 213, pp. 530-536
Pieterman, R.M., Van Putten, J.W., Meuzelaar, J.J., Preoperative staging of non-small-cell lung cancer with positron-emission tomography (2000) N. Engl. J. Med., 343, pp. 254-261
Laking, G., Price, P., 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer (2001) Thorax, 56 (SUPPL. 2), pp. 38-ii44
Gambhir, S.S., Hoh, C.K., Phelps, M.E., Madar, I., Maddahi, J., Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma (1996) J. Nucl. Med., 37, pp. 1428-1436
Van Tinteren, H., Hoekstra, O.S., Smit, E.F., Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial (2002) Lancet, 359, pp. 1388-1393
Boyer MJ, Viney R, Fulham M. A randomized trial of conventional staging (CS) in patients (pts) with stage 1 or 2 non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 20, 309a (abstr #1233)
Poncelet, A.J., Lonneux, M., Coche, E., Weynand, B., Noirhomme, P., PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma (2001) Eur. J. Cardiothorac. Surg., 20, pp. 468-474
Wagner, J.D., Schauwecker, D., Davidson, D., Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy (1999) J. Clin. Oncol., 17, pp. 1508-1515
Acland, K.M., Healy, C., Calonje, E., Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma (2001) J. Clin. Oncol., 19, pp. 2674-2678
Avril, N., Dose, J., Janicke, F., Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (1996) J. Natl. Cancer Inst., 88, pp. 1204-1209
Flanagan, F.L., Dehdashti, F., Ogunbiyi, O.A., Kodner, I.J., Siegel, B.A., Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer (1998) Ann. Surg., 227, pp. 319-323
Simo, M., Lomena, F., Setoain, J., FDG-PET improves the management of patients with suspected recurrence of colorectal cancer (2002) Nucl. Med. Commun., 23, pp. 975-982
Huebner, R.H., Park, K.C., Shepherd, J.E., A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer (2000) J. Nucl. Med., 41, pp. 1177-1189
Strasberg, S.M., Dehdashti, F., Siegel, B.A., Drebin, J.A., Linehan, D., Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study (2001) Ann. Surg., 233, pp. 293-299
Ruers, T.J., Langenhoff, B.S., Neeleman, N., Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study (2002) J. Clin. Oncol., 20, pp. 388-395
Kinkel, K., Lu, Y., Both, M., Warren, R.S., Thoeni, R.F., Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis (2002) Radiology, 224, pp. 748-756
Jerusalem, G., Beguin, Y., Fassotte, M.F., Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging (1999) Blood, 94, pp. 429-433
Zinzani, P.L., Magagnoli, M., Chierichetti, F., The role of positron emission tomography (PET) in the management of lymphoma patients (1999) Ann. Oncol., 10, pp. 1181-1184
Spaepen, K., Stroobants, S., Dupont, P., Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? (2001) J. Clin. Oncol., 19, pp. 414-419
De Wit, M., Bohuslavizki, K.H., Buchert, R., 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma (2001) Ann. Oncol., 12, pp. 29-37
Weihrauch, M.R., Re, D., Scheidhauer, K., Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease (2001) Blood, 98, pp. 2930-2934
Jerusalem, G., Beguin, Y., Commentary on "Positron emission tomography in lymphoma: Comparison with computed tomography and gallium-67 single photon emission computed tomography" (2000) Clin. Lymphoma, 1, pp. 75-76
Ganjoo, K.N., Chan, R.J., Sharma, M., Einhorn, L.H., Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma (1999) J. Clin. Oncol., 17, pp. 3457-3460
De Santis, M., Bokemeyer, C., Becherer, A., Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma (2001) J. Clin. Oncol., 19, pp. 3740-3744
Kollmannsberger, C., Oechsle, K., Dohmen, B.M., Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma (2002) Cancer, 94, pp. 2353-2362
Schechter, N.R., Gillenwater, A.M., Byers, R.M., Can positron emission tomography improve the quality of care for head-and-neck cancer patients? (2001) Int. J. Radiat. Oncol. Biol. Phys., 51, pp. 4-9
Lonneux, M., Lawson, G., Ide, C., Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient (2000) Laryngoscope, 110, pp. 1493-1497
Ogawa, T., Kanno, I., Shishido, F., Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury (1991) Acta Radiol., 22, pp. 197-202
Jerusalem, G., Beguin, Y., Fassotte, M.F., Early detection of relapse by whole-body positron emission tomography (PET) in the follow-up of patients with Hodgkin's disease (HD) (2003) Ann. Oncol., 14, pp. 123-130
Tyler, D.S., Onaitis, M., Kherani, A., Positron emission tomography scanning in malignant melanoma (2000) Cancer, 89, pp. 1019-1025
Mijnhout, G.S., Hoekstra, O.S., Van Tulder, M.W., Teule, G.J., Deville, W.L., Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients (2001) Cancer, 91, pp. 1530-1542
Hoekstra, C.J., Hoekstra, O.S., Stroobants, S.G., Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET (2002) J. Nucl. Med., 43, pp. 1304-1309
Ahuja, V., Coleman, R.E., Herndon, J., Patz E.F., Jr., The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma (1998) Cancer, 83, pp. 918-924
Vansteenkiste, J.F., Stroobants, S.G., Dupont, P.J., Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group (1999) J. Clin. Oncol., 17, pp. 3201-3206
Jerusalem, G., Beguin, Y., Fassotte, M.F., Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma (2000) Haematologica, 85, pp. 613-618
Jerusalem, G., Beguin, Y., Fassotte, M.F., [Early treatment evaluation by positron emission tomography] (2000) Med. Hyg., 58, pp. 1629-1632. , [in French]
Young, H., Baum, R., Cremerius, U., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group (1999) Eur. J. Cancer, 35, pp. 1773-1782
Shreve, P.D., Grossman, H.B., Gross, M.D., Wahl, R.L., Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose (1996) Radiology, 199, pp. 751-756
Jerusalem, G., Beguin, Y., Najjar, F., Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL) (2001) Ann. Oncol., 12, pp. 825-830
Laking, G.R., Price, P.M., Sculpher, M.J., Assessment of the technology for functional imaging in cancer (2002) Eur. J. Cancer, 38, pp. 2194-2199
Cook, G.J., Fogelman, I., Maisey, M.N., Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation (1996) Semin. Nucl. Med., 26, pp. 308-314